This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alvirez-Freites, E. J.
Right arrow Articles by Cynamon, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alvirez-Freites, E. J.
Right arrow Articles by Cynamon, M. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2002, p. 1022-1025, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1022-1025.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis

Enrique J. Alvirez-Freites,1 Janna L. Carter,2 and Michael H. Cynamon1,2*

Department of Microbiology and Immunology, Upstate Medical University, State University of New York,1 Department of Medicine, Veterans Affairs Medical Center, Syracuse, New York2

Received 19 November 2001/ Returned for modification 10 December 2001/ Accepted 14 January 2002

Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis. GAT was subsequently compared in a dose range study to isoniazid (INH) in a murine tuberculosis model. GAT was somewhat less active than INH. GAT and MXF were evaluated in mice infected with M. tuberculosis and were found to have similar activities. GAT was studied alone and in combination with ethambutol, ethionamide (ETA), and pyrazinamide (PZA) and compared to INH and rifampin (RIF). GAT appears to have sufficient activity alone and in combination with ETA with or without PZA to merit evaluation for treatment of tuberculosis.

* Corresponding author. Mailing address: VAMC, 800 Irving Ave., Syracuse, NY 13210. Phone: (315) 476-7461, ext. 3324. Fax: (315) 476-5348. E-mail: Michael.Cynamon{at}med.va.gov.

Antimicrobial Agents and Chemotherapy, April 2002, p. 1022-1025, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1022-1025.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shiraishi, Y., Katsuragi, N., Kita, H., Tominaga, Y., Kariatsumari, K., Onda, T. (2009). Aggressive surgical treatment of multidrug-resistant tuberculosis.. J. Thorac. Cardiovasc. Surg. 138: 1180-1184 [Abstract] [Full Text]  
  • Von Groll, A., Martin, A., Jureen, P., Hoffner, S., Vandamme, P., Portaels, F., Palomino, J. C., da Silva, P. A. (2009). Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53: 4498-4500 [Abstract] [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Kohno, Y., Ohno, H., Miyazaki, Y., Higashiyama, Y., Yanagihara, K., Hirakata, Y., Fukushima, K., Kohno, S. (2007). In Vitro and In Vivo Activities of Novel Fluoroquinolones Alone and in Combination with Clarithromycin against Clinically Isolated Mycobacterium avium Complex Strains in Japan. Antimicrob. Agents Chemother. 51: 4071-4076 [Abstract] [Full Text]  
  • Malik, M., Drlica, K. (2006). Moxifloxacin Lethality against Mycobacterium tuberculosis in the Presence and Absence of Chloramphenicol.. Antimicrob. Agents Chemother. 50: 2842-2844 [Abstract] [Full Text]  
  • Malik, M., Lu, T., Zhao, X., Singh, A., Hattan, C. M., Domagala, J., Kerns, R., Drlica, K. (2005). Lethality of Quinolones against Mycobacterium smegmatis in the Presence or Absence of Chloramphenicol. Antimicrob. Agents Chemother. 49: 2008-2014 [Abstract] [Full Text]  
  • Nikonenko, B. V., Samala, R., Einck, L., Nacy, C. A. (2004). Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48: 4550-4555 [Abstract] [Full Text]  
  • Shoen, C. M., DeStefano, M. S., Sklaney, M. R., Monica, B. J., Slee, A. M., Cynamon, M. H. (2004). Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. J Antimicrob Chemother 53: 641-645 [Abstract] [Full Text]  
  • Rodriguez, J. C., Cebrian, L., Lopez, M., Ruiz, M., Jimenez, I., Royo, G. (2004). Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 53: 441-444 [Abstract] [Full Text]  
  • Lu, T., Drlica, K. (2003). In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52: 1025-1028 [Abstract] [Full Text]  
  • O'Brien, R. J. (2003). Development of Fluoroquinolones as First-line Drugs for Tuberculosis--at Long Last!. Am. J. Respir. Crit. Care Med. 168: 1266-1268 [Full Text]  
  • Veziris, N., Truffot-Pernot, C., Aubry, A., Jarlier, V., Lounis, N. (2003). Fluoroquinolone-Containing Third-Line Regimen against Mycobacterium tuberculosis In Vivo. Antimicrob. Agents Chemother. 47: 3117-3122 [Abstract] [Full Text]  
  • Cynamon, M. H., Sklaney, M. (2003). Gatifloxacin and Ethionamide as the Foundation for Therapy of Tuberculosis. Antimicrob. Agents Chemother. 47: 2442-2444 [Abstract] [Full Text]  
  • Cynamon, M. H., Elliott, S. A., DeStefano, M. S., Yeo, A. E. T. (2003). Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection. J Antimicrob Chemother 52: 306-307 [Abstract] [Full Text]  
  • Hu, Y., Coates, A. R. M., Mitchison, D. A. (2003). Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47: 653-657 [Abstract] [Full Text]  
  • Fattorini, L., Tan, D., Iona, E., Mattei, M., Giannoni, F., Brunori, L., Recchia, S., Orefici, G. (2003). Activities of Moxifloxacin Alone and in Combination with Other Antimicrobial Agents against Multidrug-Resistant Mycobacterium tuberculosis Infection in BALB/c Mice. Antimicrob. Agents Chemother. 47: 360-362 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»